The role of glycans in the development and progression of prostate cancer
暂无分享,去创建一个
[1] M. Herlyn,et al. Monoclonal antibody detection of a circulating tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma , 1982, Journal of Clinical Immunology.
[2] P. Lange,et al. Sialyl-Lewis(x) and related carbohydrate antigens in the prostate. , 1995, Human pathology.
[3] H. Kobayashi,et al. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] G. Hart,et al. O-linked beta-N-acetylglucosamine (O-GlcNAc): Extensive crosstalk with phosphorylation to regulate signaling and transcription in response to nutrients and stress. , 2010, Biochimica et biophysica acta.
[5] R. Matthiesen,et al. Differential expression of alpha-2,3-sialyltransferases and alpha-1,3/4-fucosyltransferases regulates the levels of sialyl Lewis a and sialyl Lewis x in gastrointestinal carcinoma cells. , 2010, The international journal of biochemistry & cell biology.
[6] D. Kletsas,et al. The greatly increased amounts of accumulated versican and decorin with specific post-translational modifications may be closely associated with the malignant phenotype of pancreatic cancer. , 2006, Biochimica et biophysica acta.
[7] Pauline M Rudd,et al. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. , 2003, Glycobiology.
[8] Geng Zhang,et al. Suppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid marker , 2009, Proceedings of the National Academy of Sciences.
[9] T. Kislinger,et al. The proteomics of prostate cancer exosomes , 2014, Expert review of proteomics.
[10] O. Grace,et al. Stromal Expression of Decorin, Semaphorin6D, SPARC, Sprouty1 and Tsukushi in Developing Prostate and Decreased Levels of Decorin in Prostate Cancer , 2012, PloS one.
[11] U. Schumacher,et al. Lectin histochemistry of resected adenocarcinoma of the lung: helix pomatia agglutinin binding is an independent prognostic factor. , 2002, The American journal of pathology.
[12] V. Kosma,et al. High stromal versican expression predicts unfavourable outcome in oral squamous cell carcinoma , 2006, Journal of Clinical Pathology.
[13] I. Mills,et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis , 2011, The EMBO journal.
[14] B. Benacerraf,et al. Monoclonal antibodies to tissue-specific cell surface antigens. I. Characterization of an antibody to a prostate tissue antigen. , 1984, Clinical immunology and immunopathology.
[15] K. Shimada,et al. Syndecan‐1 (CD138) contributes to prostate cancer progression by stabilizing tumour‐initiating cells , 2013, The Journal of pathology.
[16] M. Aebi,et al. Mechanisms and principles of N-linked protein glycosylation. , 2011, Current opinion in structural biology.
[17] Peng Gao,et al. Matrix assisted laser desorption ionization imaging mass spectrometry workflow for spatial profiling analysis of N-linked glycan expression in tissues. , 2013, Analytical chemistry.
[18] Minoru Fukuda,et al. Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy. , 2004, Glycobiology.
[19] 崇行 上垣内. Overexpression of O-GlcNAc by prostate cancer cells is significantly associated with poor prognosis of patients(前立腺癌細胞におけるO-GlcNAcの過剰発現は前立腺患者の予後不良と密接に関連している) , 2014 .
[20] P. Robbins,et al. Glycotyping of prostate specific antigen. , 2000, Glycobiology.
[21] A. Bassols,et al. Versican is differentially expressed in human melanoma and may play a role in tumor development. , 2002, The American journal of pathology.
[22] R. Cummings,et al. Simple sugars to complex disease--mucin-type O-glycans in cancer. , 2015, Advances in cancer research.
[23] E. Stura,et al. Crystal structure of human prostate-specific antigen in a sandwich antibody complex. , 2011, Journal of molecular biology.
[24] S. Dhanasekaran,et al. Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.
[25] H. Klocker,et al. Expression of Lewis carbohydrate antigens in metastatic lesions from human prostatic carcinoma , 1998, The Prostate.
[26] M. Sobrinho-Simões,et al. Dimeric sialyl-Le(x) expression in gastric carcinoma correlates with venous invasion and poor outcome. , 1998, Gastroenterology.
[27] D. Horsfall,et al. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] D. Horsfall,et al. Formation of Hyaluronan- and Versican-rich Pericellular Matrix by Prostate Cancer Cells Promotes Cell Motility* , 2007, Journal of Biological Chemistry.
[29] P. Humphrey,et al. Gleason grading and prognostic factors in carcinoma of the prostate , 2004, Modern Pathology.
[30] R. Wolfinger,et al. Anti‐Oligomannose Antibodies as Potential Serum Biomarkers of Aggressive Prostate Cancer , 2013, Drug development research.
[31] D. Elliott,et al. Hallmarks of glycosylation in cancer , 2016, Oncotarget.
[32] Benjamin A. Neely,et al. MALDI Imaging Mass Spectrometry Profiling of N-Glycans in Formalin-Fixed Paraffin Embedded Clinical Tissue Blocks and Tissue Microarrays , 2014, PloS one.
[33] H. Nakanishi,et al. Enhancement of metastatic ability by ectopic expression of ST6GalNAcI on a gastric cancer cell line in a mouse model , 2012, Clinical & Experimental Metastasis.
[34] S. Baldus,et al. Histopathological Subtypes and Prognosis of Gastric Cancer Are Correlated with the Expression of Mucin-Associated Sialylated Antigens: Sialosyl-Lewisa, Sialosyl-Lewisx and Sialosyl-Tn , 1998, Tumor Biology.
[35] S. Tsuboi,et al. Core2 O-glycan-expressing prostate cancer cells are resistant to NK cell immunity , 2012, Molecular medicine reports.
[36] P. Conroy,et al. Aberrant PSA glycosylation—a sweet predictor of prostate cancer , 2013, Nature Reviews Urology.
[37] Y. Kaneda,et al. Androgen-Regulated Transcriptional Control of Sialyltransferases in Prostate Cancer Cells , 2012, PloS one.
[38] I. Edwards. Proteoglycans in prostate cancer , 2012, Nature Reviews Urology.
[39] J. Hanover,et al. JCB_201501101 1..12 , 2015 .
[40] M. Dwek,et al. A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia. , 2010, Clinica chimica acta; international journal of clinical chemistry.
[41] M. Tajiri,et al. Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach. , 2008, Glycobiology.
[42] Carolyn R. Bertozzi,et al. Essentials of Glycobiology , 1999 .
[43] M. Emberton,et al. Management of low risk prostate cancer: active surveillance and focal therapy , 2014, Current opinion in urology.
[44] Damien Y. Duveau,et al. Inhibition of O-GlcNAc transferase activity reprograms prostate cancer cell metabolism , 2016, Oncotarget.
[45] M. Barry. Prostate-Specific–Antigen Testing for Early Diagnosis of Prostate Cancer , 2001 .
[46] Y. Sato,et al. Structural characteristics of the N-glycans of two isoforms of prostate-specific antigens purified from human seminal fluid. , 2001, Biochimica et biophysica acta.
[47] Yue Fan,et al. Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. , 2011, Glycobiology.
[48] K. Shimada,et al. Syndecan‐1 up‐regulates microRNA‐331‐3p and mediates epithelial‐to‐mesenchymal transition in prostate cancer , 2016, Molecular carcinogenesis.
[49] H. Scher,et al. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] K. Pienta,et al. Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking , 2009, Proceedings of the National Academy of Sciences.
[51] A. Furlan,et al. ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. , 2006, Glycobiology.
[52] P. Deyn,et al. Serum N-glycan profile shift during human ageing , 2010, Experimental Gerontology.
[53] K. Tsui,et al. Evaluating the function of matriptase and N-acetylglucosaminyltransferase V in prostate cancer metastasis. , 2008, Anticancer research.
[54] Hui Zhang,et al. Overexpression of α (1,6) fucosyltransferase associated with aggressive prostate cancer. , 2014, Glycobiology.
[55] Udo Schumacher,et al. Aberrant Presentation of HPA-Reactive Carbohydrates Implies Selectin-Independent Metastasis Formation in Human Prostate Cancer , 2014, Clinical Cancer Research.
[56] V. Reuter,et al. Immunophenotype of High-Grade Prostatic Adenocarcinoma and Urothelial Carcinoma , 2000, Modern Pathology.
[57] R. Vessella,et al. Human Prostate Cancer in a Clinically Relevant Xenograft Mouse Model: Identification of β(1,6)-Branched Oligosaccharides as a Marker of Tumor Progression , 2012, Clinical Cancer Research.
[58] D. Peehl,et al. Carbohydrate Sequence of the Prostate Cancer-associated Antigen F77 Assigned by a Mucin O-Glycome Designer Array , 2014, The Journal of Biological Chemistry.
[59] Haixu Tang,et al. Interlaboratory Study on Differential Analysis of Protein Glycosylation by Mass Spectrometry: The ABRF Glycoprotein Research Multi-Institutional Study 2012* , 2013, Molecular & Cellular Proteomics.
[60] Ankita Patel,et al. PGM3 mutations cause a congenital disorder of glycosylation with severe immunodeficiency and skeletal dysplasia. , 2014, American journal of human genetics.
[61] J. O'flaherty,et al. Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. , 2009, Neoplasia.
[62] I. Mills,et al. The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer , 2015, Oncotarget.
[63] Denong Wang. N-glycan Cryptic Antigens as Active Immunological Targets in Prostate Cancer Patients , 2012, Journal of proteomics & bioinformatics.
[64] Naoyuki Taniguchi,et al. Glycans and cancer: role of N-glycans in cancer biomarker, progression and metastasis, and therapeutics. , 2015, Advances in cancer research.
[65] M. Reginato,et al. Critical Role of O-Linked β-N-Acetylglucosamine Transferase in Prostate Cancer Invasion, Angiogenesis, and Metastasis* , 2012, The Journal of Biological Chemistry.
[66] R. Bast,et al. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. , 1984, Cancer research.
[67] S. Hakomori,et al. Glycolipids of hamster fibroblasts and derived malignant-transformed cell lines. , 1968, Proceedings of the National Academy of Sciences of the United States of America.
[68] J. Hanover,et al. The Hexosamine Signaling Pathway: Deciphering the "O-GlcNAc Code" , 2005, Science's STKE.
[69] T. Irimura,et al. Expression of sialylated MUC1 in prostate cancer: Relationship to clinical stage and prognosis , 2005, International journal of urology : official journal of the Japanese Urological Association.
[70] R. Dwek,et al. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA. , 2006, Glycobiology.
[71] J. Dekernion,et al. Cell surface blood group antigens in prostatic carcinoma. , 1984, American journal of clinical pathology.
[72] T. Habuchi,et al. Serum tri‐ and tetra‐antennary N‐glycan is a potential predictive biomarker for castration‐resistant prostate cancer , 2014, The Prostate.
[73] J. Nyalwidhe,et al. Altered glycosylation in prostate cancer. , 2015, Advances in cancer research.
[74] I. Mills,et al. UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation , 2014, Oncogene.
[75] J. Munkley. The Role of Sialyl-Tn in Cancer , 2016, International journal of molecular sciences.
[76] Lai-Xi Wang,et al. Enhanced immune recognition of cryptic glycan markers in human tumors. , 2009, Cancer research.
[77] Philip East,et al. Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes , 2014, BMC Medical Genomics.
[78] P. Rudd,et al. Glycan characterization of PSA 2-DE subforms from serum and seminal plasma. , 2010, Omics : a journal of integrative biology.
[79] D. Horsfall,et al. Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer. , 1999, Cancer research.
[80] S. Brosman,et al. Gangliosides of organ-confined versus metastatic androgen-receptor-negative prostate cancer. , 2004, Biochemical and biophysical research communications.
[81] J. Hanover,et al. Bittersweet memories: linking metabolism to epigenetics through O-GlcNAcylation , 2012, Nature Reviews Molecular Cell Biology.
[82] Mary Ann Comunale,et al. Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. , 2009, Journal of proteome research.
[83] J. Olsen,et al. Immature truncated O-glycophenotype of cancer directly induces oncogenic features , 2014, Proceedings of the National Academy of Sciences.
[84] I. Mills. Maintaining and reprogramming genomic androgen receptor activity in prostate cancer , 2014, Nature Reviews Cancer.
[85] K. Shimada,et al. Syndecan-1 responsive microRNA-126 and 149 regulate cell proliferation in prostate cancer. , 2015, Biochemical and biophysical research communications.
[86] J. Brooks,et al. Increased expression of GCNT1 is associated with altered O‐glycosylation of PSA, PAP, and MUC1 in human prostate cancers , 2014, The Prostate.
[87] Andrew J. Vickers,et al. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring , 2008, Nature Reviews Cancer.
[88] Dragana Nikitovic,et al. Glycosaminoglycans: key players in cancer cell biology and treatment , 2012, The FEBS journal.
[89] H. Kobayashi,et al. Sialyl Tn as a prognostic marker in epithelial ovarian cancer. , 1992, British Journal of Cancer.
[90] J. Comet,et al. Differential percentage of serum prostate‐specific antigen subforms suggests a new way to improve prostate cancer diagnosis , 2010, The Prostate.
[91] D. Peehl,et al. Determination of Carbohydrate Structure Recognized by Prostate-specific F77 Monoclonal Antibody through Expression Analysis of Glycosyltransferase Genes , 2014, The Journal of Biological Chemistry.
[92] Y. Mechref,et al. Alterations in the serum glycome due to metastatic prostate cancer. , 2007, Journal of proteome research.
[93] C. Ohyama,et al. Expression of core 2 beta1,6-N-acetylglucosaminyltransferase facilitates prostate cancer progression. , 2005, Glycobiology.
[94] U. Schumacher,et al. Lectin binding to cutaneous malignant melanoma: HPA is associated with metastasis formation , 2001, British Journal of Cancer.
[95] I. Mills,et al. O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. , 2013, Cancer research.
[96] J. Kench,et al. Immunohistochemical Level of Unsulfated Chondroitin Disaccharides in the Cancer Stroma Is an Independent Predictor of Prostate Cancer Relapse , 2008, Cancer Epidemiology Biomarkers & Prevention.
[97] A. Ivy,et al. INCIDENCE OF THE BLOOD GROUPS AND THE SECRETOR FACTOR IN PATIENTS WITH PERNICIOUS ANEMIA AND STOMACH CARCINOMA , 1949, The American journal of the medical sciences.
[98] S. Hakomori,et al. Glycosphingolipids as tumor-associated and differentiation markers. , 1983, Journal of the National Cancer Institute.
[99] Michael J Barry,et al. Screening for prostate cancer--the controversy that refuses to die. , 2009, The New England journal of medicine.
[100] D. Chan,et al. Aberrant glycosylation associated with enzymes as cancer biomarkers , 2011, Clinical Proteomics.
[101] D. Horsfall,et al. Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[102] S. Pinho,et al. Glycosylation in cancer: mechanisms and clinical implications , 2015, Nature Reviews Cancer.
[103] Renato V Iozzo,et al. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis , 2011, Journal of cellular and molecular medicine.
[104] F. Schmitt,et al. Expression of sialyl-Tn in breast cancer. Correlation with prognostic parameters. , 1996, Pathology, research and practice.
[105] Hui Zhang,et al. Integrated Proteomic and Glycoproteomic Analyses of Prostate Cancer Cells Reveal Glycoprotein Alteration in Protein Abundance and Glycosylation* , 2015, Molecular & Cellular Proteomics.
[106] S. Baba,et al. alpha1,2-Fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer. , 2010, Glycobiology.
[107] Rajiv Dhir,et al. Perlecan, a candidate gene for the CAPB locus, regulates prostate cancer cell growth via the Sonic Hedgehog pathway , 2006, Molecular Cancer.
[108] T. Habuchi,et al. Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer. , 2014, Biochemical and biophysical research communications.
[109] A. V. Suhovskih,et al. Proteoglycan Expression in Normal Human Prostate Tissue and Prostate Cancer , 2013, ISRN oncology.
[110] Y. Kakeji,et al. Helix pomatia agglutinin binding activity is a predictor of survival time for patients with gastric carcinoma , 1991 .
[111] J. Schlom,et al. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. , 1986, Cancer research.
[112] I. Mills,et al. N-Linked Glycosylation Supports Cross-Talk between Receptor Tyrosine Kinases and Androgen Receptor , 2013, PloS one.
[113] S. Kitahara,et al. Serial lectin affinity chromatography with concavalin A and wheat germ agglutinin demonstrates altered asparagine-linked sugar-chain structures of prostatic acid phosphatase in human prostate carcinoma. , 1997, Journal of chromatography. B, Biomedical sciences and applications.
[114] J. Schlom,et al. Tumor associated glycoprotein-72 is highly expressed in prostatic adenocarcinomas. , 1994, The Journal of urology.
[115] H. Danielsen,et al. Up-regulation of the oligosaccharide sialyl LewisX: a new prognostic parameter in metastatic prostate cancer. , 1995, Cancer research.
[116] U. Schumacher,et al. The use of the lectin Helix pomatia agglutinin (HPA) as a prognostic indicator and as a tool in cancer research. , 1999, Histology and histopathology.
[117] I. Mills,et al. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. , 2013, Cancer cell.